AIM ImmunoTech Secures Long COVID Patent Protection in Europe Through 2041
Event summary
- AIM ImmunoTech secured three patents in Europe and the UK for Ampligen's use in treating Long COVID, valid through June 2041.
- The patents cover specific dosing regimens and delivery methods, including intranasal, intravenous, and inhalation administration.
- This follows a newly issued U.S. patent for Ampligen in combination with pembrolizumab for cancer treatment.
- The patents apply to 18 European countries, including Germany, France, Italy, and the UK.
- Ampligen has undergone extensive clinical testing with over 1,200 patients and 100,000 doses administered.
The big picture
AIM ImmunoTech is strategically expanding its Ampligen patent estate, reinforcing its position in both cancer and Long COVID treatment markets. This move aligns with broader industry trends of biopharmaceutical companies securing long-term IP protection to maximize commercial potential. The patents extend Ampligen's market reach across key European economies, potentially increasing its valuation and attractiveness to investors.
What we're watching
- Patent Enforcement
- How AIM will defend these patents against potential infringement in major European markets.
- Commercialization Strategy
- Whether AIM can leverage this IP to secure partnerships or licensing deals for Long COVID treatment.
- Regulatory Approval
- The pace at which Ampligen advances through clinical trials and regulatory approvals for Long COVID.